Polar Capital Holdings Plc Lowers Holdings in NeuroPace, Inc. $NPCE

Posted by Geri Gentry on Jun 17th, 2026

Polar Capital Holdings Plc lessened its stake in NeuroPace, Inc. (NASDAQ:NPCE – Free Report) by 7.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,878,523 shares of the company’s stock after selling 219,345 shares during the quarter. Polar Capital Holdings Plc owned 8.64% of NeuroPace worth $44,444,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in NeuroPace by 4.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,435,850 shares of the company’s stock worth $14,804,000 after buying an additional 66,574 shares in the last quarter. Armistice Capital LLC grew its stake in shares of NeuroPace by 12.6% during the 3rd quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock valued at $13,382,000 after purchasing an additional 145,665 shares during the period. Geode Capital Management LLC grew its stake in shares of NeuroPace by 6.5% during the 4th quarter. Geode Capital Management LLC now owns 596,248 shares of the company’s stock valued at $9,208,000 after purchasing an additional 36,516 shares during the period. State Street Corp grew its stake in shares of NeuroPace by 9.8% during the 4th quarter. State Street Corp now owns 447,864 shares of the company’s stock valued at $6,915,000 after purchasing an additional 40,025 shares during the period. Finally, Divisadero Street Capital Management LP grew its stake in shares of NeuroPace by 20.9% during the 3rd quarter. Divisadero Street Capital Management LP now owns 292,792 shares of the company’s stock valued at $3,019,000 after acquiring an additional 50,672 shares during the period. 78.83% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroPace in a research note on Friday, March 27th. HC Wainwright boosted their price target on NeuroPace from $19.00 to $20.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Cantor Fitzgerald raised NeuroPace to a “strong-buy” rating in a report on Wednesday, March 4th. Wells Fargo & Company raised NeuroPace to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, Wall Street Zen cut NeuroPace from a “buy” rating to a “hold” rating in a report on Sunday, March 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $18.83.

Get Our Latest Analysis on NeuroPace

NeuroPace Stock Down 2.3%

NASDAQ NPCE opened at $15.02 on Wednesday. The stock’s 50 day moving average is $16.17 and its 200 day moving average is $15.63. The company has a current ratio of 5.38, a quick ratio of 4.35 and a debt-to-equity ratio of 4.08. NeuroPace, Inc. has a 12 month low of $7.56 and a 12 month high of $19.60. The stock has a market cap of $512.03 million, a PE ratio of -23.11 and a beta of 1.88.

NeuroPace (NASDAQ:NPCE – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06. NeuroPace had a negative return on equity of 108.20% and a negative net margin of 21.67%.The company had revenue of $22.00 million for the quarter, compared to analysts’ expectations of $21.65 million. Research analysts predict that NeuroPace, Inc. will post -0.54 EPS for the current fiscal year.

NeuroPace Profile

(Free Report)

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.